Biogen’s chances of getting an FDA approval for its tofersen drug candidate for amyotrophic lateral sclerosis (ALS) patients who have mutations in the SOD1 gene have been
The FDA has said it cannot approve AbbVie’s Parkinson’s disease drug ABBV-951, designed to provide continuous control of symptoms, saying it needs more information about t
Roche and Eli Lilly have started testing a blood test that could be used to diagnose Alzheimer’s before symptoms arise, providing an alternative to expensive brain scans a
Swiss biotech Noema has added another $112 million to its funding in an oversubscribed second round, as it takes neurological disorder drugs licensed in from Roche through
Eisai and partner Biogen have edged closer to a full FDA approval of their Alzheimer’s disease therapy Leqembi, after the US regulator set a 6th July date for their market
Inato has raised $20 million in early-stage financing to support the continued development of its clinical trial marketplace, which connects sponsors with its network of t